Noordwest Ziekenhuisgroep   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Alkmaar Denmark (1930)

Organization Overview

First Clinical Trial
2002
NCT00170222
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

MCA Alkmaar | Medical Center Alkmaar | Medical Center Alkmaar, dep. Pulmomary Diseases | Medical Center of Alkmaar | Medisch Centrum Alkmaar | Noordwest Ziekenhuisgroep | Zorggroep Noordwest-Veluwe

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Adenocarcinoma (Phase 2)

Angina, Unstable (Phase 4)

Bronchiectasis (Phase 3)

Colonic Neoplasms (Phase 4)

Emphysema (Phase 4)

Esophageal Neoplasms (Phase 2)

Heart Arrest (Phase 2)

Infarction (Phase 4)

Inflammation (Phase 4)

Intermittent Claudication (Phase 3)

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Myocardial Infarction (Phase 4)

Non-ST Elevated Myocardial Infarction (Phase 4)

Obesity, Morbid (Phase 4)

Pneumonia (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Pulmonary Emphysema (Phase 4)

Syndrome (Phase 4)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 20